FDA Approves Horizant for PHN; GSK Promotion Role 'Up in Air'
By Catherine Shaffer
Friday, June 8, 2012
Shares of XenoPort Inc. plunged 9.6 percent Thursday as investors frantically shorted the stock that had run up to more than $6 in anticipation of the PDUFA date for Horizant (gabapentin enacarbil) extended-release tablets for postherpetic neuralgia (PHN) in adults, an event that triggered a $10 million milestone payment from partner GlaxoSmithKline plc.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.